.png)
DNA next generation sequencing (NGS) assay designed to analyze 302 genes associated with various hematologic cancers including:
Myelodysplastic syndrome(MDS)/Chronic myelomonocytic leukemia (CMML): It helps in determining prognosis and selecting therapy, also if the patient has reactive cytopenia and will distinguish between CHIP (Clonal Hematopoiesis of Indeterminate Potential) orCCUS (Clonal Cytopenia of Unknown Significance) and MDS.
VEXAS Syndrome: Recently VEXAS(vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is caused by mutations in the UBA1 gene.
Acute Myeloid Leukemia (AML): It helps in the diagnosis of AML and distinguishes between De Novo AML vs secondary AML. It also helps in determining eligibility for treatment with FLT3 and IDH1/2 inhibitors.
Myeloproliferative Neoplasms(MPN): This includes quantitative analysis of all exons of JAK2, CALR, and MPL.
Lymphoma: Analysis of mutations reported in various types of lymphoma, including follicular, DLBCL, CLL, and T-cell lymphoma.
Multiple Myeloma: It detects mutations in the coding sequence of genes frequently mutated.
Bone marrow: 2 mL; EDTA tube is preferred.
Peripheral blood: 5-10 mL; EDTA tube is preferred.
Fresh Tissue
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of BM clot or tissue fixed with 10% NBF fixative. Alternatively, the FFPE block of the BM clot can be sent for sectioning in our Lab.
Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.